Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1979
Title: Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio a Syndrome: A Phase 3b Study
Authors: Owens, Penny ;Bhattacharya, K.;Balasubramaniam, S.;Murray, K.;Peters, H.;Ketteridge, D.;Inwood, A.;Lee, J.;Ellaway, C.;Wong, M.
Affliation: Central Coast Local Health District
Issue Date: 2020
Source: 8:e20200001
Journal title: Journal of Inborn Errors of Metabolism and Screening
Department: Paediatrics
Abstract: Abstract The safety and efficacy of elosulfase alfa were evaluated in a multicenter, open-label, phase 3b study in Australian Morquio A patients, consisting of a 49-week initial phase and an extension phase until elosulfase alfa was government funded. Thirteen patients (1-27 years) were enrolled. No new safety concerns were identified over 138 weeks. Most drug-related adverse events were mild or moderate in severity; none led to study discontinuation. After 49 weeks of treatment, median improvements from baseline were seen in the 6-minute walk test (+41.0 m), 3-minute stair climb test (+14.0 stairs/min), forced vital capacity (+16.4%), forced expiratory volume in 1 second (+14.1%), urine keratan sulfate (-7.1 µg/mg creatinine), and pain intensity. Growth, cardiac function, sleep, and quality of life results were mixed or stable. These results provide further evidence of the acceptable safety/tolerability profile of elosulfase alfa. The improvements in endurance, pulmonary function, and pain support findings from previous studies.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1979
DOI: 10.1590/2326-4594-JIEMS-2020-0001
ISSN: 2326-4594
Publicaton type: Journal Article
Study or Trial: Multicentre Studies
Appears in Collections:Health Service Research

Show full item record

Page view(s)

12
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.